BIOMARIN PHARMACEUTICAL INC.

Registrant on federal lobbying filings · filed 2025 to 2026

$0 Income reported

1 Clients represented

6 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. It also reported $2,190,000 of in-house lobbying expenses, which is what a registrant files when it lobbies for itself. 2 filings on this record were restated by a later amendment and are left out of every total here. Everything on this page is grouped by the registrant's LDA id (401049958), not by name.

Clients 1

BIOMARIN PHARMACEUTICAL INC. $2,190,000 6 filings

Lobbyists named 1

DANIEL MAYNE 3 filings · through 2026 SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024)

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

Reported by year 2 years

2026 $870,000 2 filings
2025 $1,320,000 4 filings

Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 7

HOUSE OF REPRESENTATIVES 6
SENATE 6
Commerce, Dept of (DOC) 4
Health & Human Services, Dept of (HHS) 3
Food & Drug Administration (FDA) 2
Executive Office of the President (EOP) 1
Health Resources & Services Administration (HRSA) 1

Recent filings 8 total

2A

BIOMARIN PHARMACEUTICAL INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $340,000 expenses · posted Jul 20, 2026

View → 2A

BIOMARIN PHARMACEUTICAL INC. Amended

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $340,000 expenses · posted Jul 20, 2026

View → Q2

BIOMARIN PHARMACEUTICAL INC. Amended

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $340,000 expenses · posted Jul 20, 2026

View → Q1

BIOMARIN PHARMACEUTICAL INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $530,000 expenses · posted Apr 20, 2026

View → Q4

BIOMARIN PHARMACEUTICAL INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $390,000 expenses · posted Jan 20, 2026

View → Q3

BIOMARIN PHARMACEUTICAL INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $270,000 expenses · posted Oct 20, 2025

View → Q2

BIOMARIN PHARMACEUTICAL INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $270,000 expenses · posted Jul 21, 2025

View → Q1

BIOMARIN PHARMACEUTICAL INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $390,000 expenses · posted Apr 21, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.